You are here

Lanthanide Radionuclide Production

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA105743-01A1
Agency Tracking Number: CA105743
Amount: $179,250.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
TDA RESEARCH, INC. 12345 W 52ND AVE
WHEAT RIDGE, CO 80033
United States
DUNS: 181947730
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOHN ALFORD
 (303) 940-2304
 JMA@TDA.COM
Business Contact
Phone: (303) 940-2300
Email: krhodus@tda.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Major advances have recently been made in the development of monoclonal antibody-based radioimmunotherapy cancer treatments, and several of these next generation antibody treatments have demonstrated good efficacy in hu
man trials and are currently awaiting FDA approval. With this new generation of highly engineered monoclonal antibodies comes the need for a wider array of commercially available radionuclides. Unfortunately, methods for producing the next generation of ra
dioisotopes has not kept pace. This Small Business Technology Transfer Phase I project will develop an improved method for the production of radionuclides used in radiopharmaceuticals. The method will allow the economical production of a wide array of lant
hanide radionuclides which can subsequently be employed for radioimmunotherapy treatments. During Phase I, a new type of Szilard-Chalmers process using pecialized lanthanide chelates will be developed and tested. The new lanthanide chelate will be synthesi
zed in bulk quantities and then the entire production process will be tested using neutron activation at the Missouri University Research Reactor. PUBLIC HEALTH RELEVANCE: Current radioisotope production relies on isotopically purified starting materials t
hat must be irradiated at the highest flux (most expensive) position in the central core of the nuclear reactor. If successful, TDA's new Szilard-Chalmers process is expected to lower production costs by allowing the use of non-isotopically purified starti
ng materials that are neutron irradiated at the more cost effective low .nux positions in the reactor.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government